MARKET

MRNS

MRNS

Marinus Pharmace
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.39
+0.07
+1.32%
Opening 15:14 05/19 EDT
OPEN
5.25
PREV CLOSE
5.32
HIGH
5.49
LOW
5.22
VOLUME
121.84K
TURNOVER
348.99K
52 WEEK HIGH
19.83
52 WEEK LOW
4.190
MARKET CAP
200.19M
P/E (TTM)
-2.1778
1D
5D
1M
3M
1Y
5Y
Marinus Pharmaceuticals to Present at Upcoming Medical and Investor Conferences
RADNOR, Pa., May 18, 2022--Marinus Pharmaceuticals to Present at Upcoming Medical and Investor Conferences
Business Wire · 1d ago
--Oppenheimer Adjusts Marinus Pharmaceuticals Price Target to $28 From $32, Maintains Outperform Rating
MT Newswires · 3d ago
Recap: Marinus Pharma Q1 Earnings
Marinus Pharma (NASDAQ:MRNS) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Marinus Pharma beat estimated earnings by 38.82%, reporting an EPS of $-0.52 versus an ...
Benzinga · 6d ago
Marinus Pharmaceuticals (MRNS) Reports Q1 Loss, Tops Revenue Estimates
Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 40.23% and 548.36%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 6d ago
Marinus Pharmaceuticals Q1 EPS $(0.52) Beats $(0.85) Estimate, Sales $14.19M Up From $1.81M YoY
Marinus Pharmaceuticals (NASDAQ:MRNS) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.85) by 38.82 percent. This is a 29.73 percent increase over losses of $(0.74) per
Benzinga · 6d ago
Marinus Pharmaceuticals GAAP EPS of -$0.52 beats by $0.33, revenue of $14.19M beats by $11.91M
Marinus Pharmaceuticals press release (NASDAQ:MRNS): Q1 GAAP EPS of -$0.52 beats by $0.33. Revenue of $14.19M (+684.0% Y/Y) beats by $11.91M.
Seekingalpha · 6d ago
BRIEF-Marinus Pharmaceuticals Reports First Quarter 2022 Results
reuters.com · 6d ago
-- Earnings Flash (MRNS) MARINUS PHARMACEUTICALS Reports Q1 Revenue $14.2M, vs. Street Est of $2.28M
MT Newswires · 05/12 16:22
More
No Data
Learn about the latest financial forecast of MRNS. Analyze the recent business situations of Marinus Pharmace through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

50.00%Strong Buy
50.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average MRNS stock price target is 30.11 with a high estimate of 50.00 and a low estimate of 17.00.
High50.00
Average30.11
Low17.00
Current 5.39
EPS
Actual
Estimate
-0.68-0.51-0.34-0.17
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 137
Institutional Holdings: 42.24M
% Owned: 114.11%
Shares Outstanding: 37.14M
TypeInstitutionsShares
Increased
23
1.01M
New
8
295.78K
Decreased
24
306.81K
Sold Out
14
2.79M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.40%
Pharmaceuticals & Medical Research
+1.01%
Key Executives
Non-Executive Chairman/Independent Director
Nicole Vitullo
President/Chief Executive Officer/Director
Scott Braunstein
Chief Financial Officer/Treasurer
Steven Pfanstiel
Vice President/General Counsel/Secretary
Martha Manning
Other
Joseph Hulihan
Independent Director
Santiago Arroyo
Independent Director
Charles Austin
Independent Director
Michael Dougherty
Independent Director
Elan Ezickson
Independent Director
Seth Fischer
Independent Director
Timothy Mayleben
Independent Director
Saraswathy Nochur
No Data
No Data
About MRNS
Marinus Pharmaceuticals Inc is a United States-based biopharmaceutical company. The Company offers development and commercialization of medical drugs for the treatment of serious neurological and psychiatric disorders such as epilepsy, post-traumatic stress, and fragile-x syndrome. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.

Webull offers kinds of Marinus Pharmaceuticals Inc stock information, including NASDAQ:MRNS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MRNS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MRNS stock methods without spending real money on the virtual paper trading platform.